PN placement: UPS DUBs and UBL demodifiers|USP|other|UBA, UIM and UPS Ubiquitin and UBL binding|DUB|USP / with UBD|UIM, UBA-like, SIM ; PN-node mapping: DUB-family group→GO:0101005 deubiquitinase activity (mapped, already_in_goa_exact); UBL-binding group→GO:0101005 (context_only, too_broad); UBL-binding class→GO:0140036 ubiquitin-modified protein reader activity (context_only); type/subtype/branch = no_mapping.
Consistency: Consistent BUT identity is the salient issue. The task framing ("USP25 was the synonym-resolved symbol for USP21") conflates two distinct genes. The folder/review (Q9UHP3) is genuinely USP25 (HGNC:12624), historically aliased "USP21"/"USP on chr 21" (PMID:10644437) — a separate protein from true USP21 (Q9UK80). The notes file documents this collision explicitly. PN dossier (Q9UHP3), review, and notes all agree on the USP25 identity; both PN rows are purely UPS (no TR/RQC row), matching the review's substrate biology (tankyrases/Wnt, KEAP1-NRF2, IL-17/TRAF, ERAD-HRD1). USP25 is NOT an RQC DUB — only true USP21 is.
PN story / NEW pressure: PN asserts only DUB activity (GO:0101005) and ubiquitin/UBL-reader context — all already in GOA/review (GO:0004843, GO:0043130 ubiquitin binding, GO:0032183 SUMO binding). No new-to-GOA projection. Conclude: already captured; no NEW term and no RQC pressure (correctly, since USP25 has no ribosome role).
Mapping strategy:USP25 does not change either node. DUB-family group→GO:0101005 is already_in_goa_exact (GOA has GO:0101005 IMP/IDA rows). UBL-binding class→GO:0140036 reader activity is correctly held as context_only/too_broad (USP25's UBA/UIM/SIM read ubiquitin and SUMO, but the class mixes modifiers). Scope/status all appropriate.
Evidence alignment: PN row 1 cites "19734957/rev"; row 2 cites PMID:18538659 (paralog-specific sumoylation) — the latter IS in the review (GO:0032183 SUMO binding, GO:0070536/GO:0071108 K63/K48 deubiquitination), good overlap. Review is far richer (KEAP1, IL-17, ERAD, epilepsy PMIDs) than the two PN rows.
Verdict: Consistent; identity confirmed as USP25 (distinct from USP21), no RQC role. PN claims already captured; no NEW term needed.